Renal function improving agent

Drug repositioning of Lubiprostone Exploratory P2 is over!

Overview

　Toxin adsorbents such as SGLT2 inhibitors and cremedin have been used as pharmacotherapy for kidney disease. Lubiprostone, which is also used as a constipation drug, was shown to be effective as a treatment for chronic kidney disease (CKD).
Lubiprostone was also found to suppress the decline in renal function.
In an investigator-initiated clinical trial, the inventors conducted an exploratory study to investigate the efficacy and safety of 8 μg/day and 16 μg/day of lubiprostone in reducing renal function in patients with chronic kidney disease, using a placebo control.
(The results can be disclosed under individual contracts.)

Features・Outstandings

Product Application

・Renal function improving agent
・Therapeutic agent for chronic kidney disease

Related Works

J Am Soc Nephrol
. 2015 Aug;26(8):1787-94. doi: 10.1681/ASN.2014060530. Epub 2014 Dec 18.

IP Data

IP No.　 ： JP6090723
Inventor ： ABE Takaaki
keyword ： Medical drug(including research tools)